During the past 14 months, 97 companies raised
After more than a month of almost no activity and a lot of speculation about whether or not investors had filled their coffers with biotech IPOs, seven companies raised almost a half billion dollars through initial public offerings during this week just before BIO 2014. Of these new offerings, only one took a deep haircut before going public.
BIO 2013 to BIO 2014: Performance of U.S. Life Sciences IPOs
• Number of IPOs 97• Capital Raised
• Number of IPOs 73• Capital Raised
"Though the issue of drug pricing, at the top of mind of stakeholders and politicians, triggered a market correction in late March and April, the biotech industry has been one of the best performers on
The Burrill Biotech Select Index has risen 35.1 percent during the period compared with the benchmark S &P 500 (up 23.2 percent), the Dow Jones Industrial Average (up 15.1 percent), and the Nasdaq Composite Index (up 31%).
Change in Value BIO 2013 - BIO 2014
• Burrill Select 35.4%• Burrill Large-Cap 34.6%• Burrill Mid-Cap 59.6%• Burrill Small-Cap 75.6%• Burrill Diagnostics 14.6%• Burrill Personalized Medicine 30.1%• NASDAQ 32.4%• DJIA 15.3%• S &P 500 24.0%• Amex Biotech 45.2%• Amex Pharmaceutical 24.0%• NASDAQ Biotechnology Index 49.4%
"Although payers, legislators, and consumer groups are up in arms over the cost of Gilead's new hepatitis C drug Sovaldi, it was the best new drug rollout ever as first quarter sales reached nearly
Issues of cost and value have also transformed the dealmaking environment since the last year's meeting in
Big Pharma awoke from its acquisition slumber with a flurry of megadeals, several of which did not succeed. While the multibillion asset swap between Novartis and GlaxoSmithKline was about achieving global dominance in areas where the drugmakers were already big players, others such as Pfizer's failed
"Pharmaceutical companies in the face of unprecedented cost pressures are seeking to become more focused and efficient than ever," Burrill says.
Burrill's newest book on the industry, Biotech 2014 – Life Sciences: Transforming Healthcare, discusses how biotechnology is transforming healthcare, even as the demands on healthcare systems today are also transforming how life sciences companies develop products and conduct business. With more than 150 charts and figures, it provides a detailed analysis of the life sciences industry, including details of financing and dealmaking numbers and trends. It is available in both the print and digital edition at discounted rate for convention attendees at the BIO bookstore and can also be purchased at www.burrillmedia.com.
Burrill Media produces publications and events focused on the global life sciences industry. Its sister company
Marie DaghlianBurrill Media email@example.com 415-341-3870